← Eichor
Condition: Recurrent Juvenile Myelomonocytic Leukemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Recurrent Juvenile Myelomonocytic Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 · 3 location(s) · M.D. Anderson Cancer Center · NCT03383575CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relap
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04375631A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS
Phase 1 · 19 location(s) · Children's Oncology Group · NCT06247787211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymph
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03128034Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Le
Phase 2 · 4 location(s) · Mayo Clinic · NCT03418038Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Lo
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT042391573'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Le
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03670966HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Le
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03896269Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutati
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03683433Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Pa
Phase 1/Phase 2 · 34 location(s) · Aptose Biosciences Inc. · NCT03850574Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MP
Phase 1 · 1 location(s) · Mayo Clinic · NCT05549661Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, M
Phase 1/Phase 2 · 1 location(s) · Uma Borate · NCT06523556Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leuk
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04140487
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.